InstellingenIk ga akkoord



Schizophrenia and bipolar disorder - Stanley Medical Research Institute Regular Treatment Trials 2013 ($ 300,000)

The Stanley Medical Research Institute (SMRI) invites applications for its Regular Treatment Trial Programme. The closing date to submit a proposal is October 1, 2013. The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. SMRI is especially interested in supporting the testing of medications that are unlikely to be tested by pharmaceutical companies because they are not commercially profitable. Regular treatment trials can be funded for up to $ 300,000 per year.

Terug naar overzicht